Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu<sub>7</sub> Negative Allosteric Modulator (NAM) in Vivo Tool Compound: <i>N</i>‑(2-(1<i>H</i>‑1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962)

Herein, we report the discovery of a new, orally bioavailable and CNS-penetrant metabotropic glutamate receptor 7 (mGlu<sub>7</sub>) negative allosteric modulator (NAM) that achieves exposure in cerebral spinal fluid (CSF) 2.5× above the in vitro IC<sub>50</sub> at minimum effective doses (MEDs) of 3 mg/kg in preclinical anxiety models.